Lung cancer is the number one cancer killer, and metastasis is the main cause of high mortality in lung cancer patients. However, mechanisms underlying the development of lung cancer metastasis remain unknown. Using genome-wide transcriptional analysis in an experimental metastasis model, we identified laminin γ2 (LAMC2), an epithelial basement membrane protein, to be significantly upregulated in lung adenocarcinoma metastatic cells. Elevated LAMC2 increased traction force, migration, and invasion of lung adenocarcinoma cells accompanied by the induction of epithelial-mesenchymal transition (EMT). LAMC2 knockdown decreased traction force, migration, and invasion accompanied by EMT reduction in vitro, and attenuated metastasis in mice. LAMC2 promoted migration and invasion via EMT that was integrin β1-and ZEB1-dependent. High LAMC2 was significantly correlated with the mesenchymal marker vimentin expression in lung adenocarcinomas, and with higher risk of recurrence or death in patients with lung adenocarcinoma. We suggest that LAMC2 promotes metastasis in lung adenocarcinoma via EMT and may be a potential therapeutic target. Non-small-cell lung cancer (NSCLC) accounts for~80-85% of lung cancers.
1
Non-small-cell lung cancer (NSCLC) accounts for~80-85% of lung cancers. 2 Only 20-30% of NSCLC are radically resectable and the majority of lung cancer patients succumb to the disease. The high mortality of NSCLC is largely attributable to late diagnosis, when metastases are present. 2 The molecular mechanisms governing metastasis of NSCLC remain poorly understood.
Metastasis is a complex, multistep process, involving migration and invasion of malignant cells from the primary tumor to blood vessels, intravasation, and survival in the circulation, and ultimately extravasation, colonization, and formation of secondary tumor at distant target organs. 3 Each of these events is classically driven by the acquisition of genetic and/or epigenetic traits in tumor cells and the cooperation of nonneoplastic stromal cells. Increased or decreased expression of several genes in tumors has been found to be correlated with metastasis. 3 However, specific gene alterations that drive NSCLC metastasis remain largely elusive.
Laminin γ2 (LAMC2) is a subunit of the heterotrimeric glycoprotein laminin-332 (LAM-332, formerly laminin-5), consisting of the α3, β3, and γ2 chains. Although LAMC2 is an important structural component of the epithelial basement membrane (BM) in various normal tissues, 4 there is an emerging evidence for a pathological role of LAMC2 monomer in cancer. It has been demonstrated that LAMC2 protein expression correlates with clinical outcome of stage I lung adenocarcinoma (ADC) patients. 5, 6 In addition, noncontinuous expression pattern of LAMC2 predicts the prognosis of esophageal squamous cell carcinoma (SCC), 7 and secreted LAMC2 in the serum is associated with the aggressiveness of pancreatic cancer. 8 Besides, LAMC2 monomer expression has been frequently found in the invasive front of epithelial tumors such as ADCs of the stomach, colon, pancreas, and lung, SCCs of the esophagus, head and neck, skin and lung, and transitional cell carcinoma of the bladder. 5, [9] [10] [11] [12] [13] [14] Epithelialmesenchymal transition (EMT) has a critical role in the early stages of dissemination of malignant epithelial tumors leading to metastatic spread. 15 There is growing evidence that LAMC2 expression increases in the carcinoma cells undergoing EMT, [16] [17] [18] and that level of LAMC2 expression is regulated directly by the EMT master regulator ZEB1 and activated β-catenin in invasive colorectal carcinoma cells. 19, 20 Combining results of gene expression microarrays with a metastasis selection model in mice, we found a robust association between metastatic derivatives of A549 lung ADC cells and increased expression of LAMC2. Here we demonstrate that LAMC2 promotes migration, invasion and metastasis in human lung ADC cells via induction of EMT. Furthermore, LAMC2 expression is prognostic in resected ADC of the lung and a potential therapeutic target. To identify genes that may be involved in metastasis, we compared mRNA expression profiles between A549 round 0 (A549R0) and A549R3 cells by microarray analysis. Expression profiles of A549 (our data) and PC9 metastatic cells (public data, GSE14107), 21 which were independently derived using the same mouse metastasis model, revealed 48 differentially expressed genes that were common in both systems, with criteria of false discovery rate o0.1 and log 2 fold change 41.5 or o − 1.5 (Figure 1c and Supplementary  Figure S1A, and Supplementary Table S1 ). Differentially expressed genes were further narrowed down to 11 based on unidirectional log 2 fold change across R1, R2, and R3, and on only genes reported to have cancer-associated function. Our microarray data demonstrated that LAMC2 was the most significantly induced gene in metastatic A549 cells and highly induced in metastatic PC9 cells, although not the most highly expressed (Figure 1c) . Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and immunoblot assays confirmed that LAMC2 was upregulated in A549R3 and A549R4, compared with A549R0 cells (Figures 1d and e) .
Results

LAMC2 is
Among the 11 differentially expressed metastasisassociated genes (Figure 1c) , we confirmed the results of RNA microarrays in 8 by real-time qRT-PCR and/or immunoblot assays in metastatic series of A549 cells derived from brain, femur, and spine metastases. Particularly evident was the upregulation of LAMC2 (Figures 1d and e) and AXL (data not shown) in A549R3 and A549R4, compared with A549R0 cells. The receptor tyrosine kinase AXL is an oncogene shown to promote tumor cell growth, metastasis, and drug resistance to HER2 and epithelial growth factor receptor-targeted therapy. [22] [23] [24] [25] LAMC2 expression has been shown to be associated with prognosis in several solid tumors, 5,9-14 but its role in the metastatic process is not clear.
LAMC2 promotes migration, invasion, and traction of lung ADC cells in concomitance with EMT. Given the implications of LAMC2 as a marker of tumor invasiveness, 5,9-14 our finding prompted us to study the potential involvement of LAMC2 in lung ADC metastasis. We observed that progressive upregulation of LAMC2 expression from A549R0 to A549R4 cells was significantly associated with increased capacity to migrate and invade Matrigels in vitro (all P-values o0.05; Figure 2a) , with the only exception of the comparison between R3-Brain and R4-Brain cells (P40.05). LAMC2 expression levels, however, had no impact on cell doubling time (Figure 2b ).
To further explore the role of LAMC2 in lung ADC metastasis, we ectopically expressed LAMC2 in four lung ADC cell lines (A549R0, PC9, H838, and H2122) with low to intermediate levels of endogenous LAMC2 expression. Compared with mock controls, stably LAMC2-transfected cells exhibited marked increases in migration and invasion (Po0.05 across all cell lines; Figure 2c ). Conversely, LAMC2-shRNA (LAMC2-short hairpin RNA) knockdown significantly reduced migration and invasion capacities of lung ADC cell lines (A549R4, PC9, H358, and H322) compared with their respective control shRNA-transfected cells (all Po0.05; Figure 2d ). Ectopic LAMC2 expression or knockdown did not affect cell proliferation (all P40.05; Supplementary Figure S2A ). Migrating cells exert traction force upon their surroundings, 26, 27 and cell traction force is necessary in cancer cell migration and invasion. 28, 29 Fourier transform traction microscopy showed that stably LAMC2-transfected A549R0 cells were bigger in size (Po0.05) and exhibited greater cell traction force (Figure 2e ), with~1.5-fold higher (Po0.05) net contractile moment compared with mock control. Similar results were observed in A549R3-Brain and A549R4-Femur cells as compared with A549R0 cells (Supplementary Figure S2B) . In contrast, LAMC2-shRNA knockdown in H358 cells (Figure 2f ) and PC9 cells (Supplementary Figure S2C) resulted in marked decreases in cell size and traction force. Consistently, H358-shLAMC2 and PC9-shLAMC2 cells attached to the surface more slowly than their corresponding control cells (all P-values o0.05; Supplementary Figures S2D and E) . These findings provide direct evidence that LAMC2 may positively regulate migration, invasion, traction, and attachment of lung ADC cells.
Epithelial-mesenchymal transition (EMT) has been linked to the early stages of dissemination of malignant epithelial tumors leading to metastatic spread. 15 We examined the expression of EMT master regulators ZEB1 or Snail. 15 Immunoblots showed that ZEB1 and/or Snail expression increased in the LAMC2-transfected cells but decreased in the LAMC2-knockdown cells compared with their corresponding control cells (Figure 2g ). Other EMT regulators such as ZEB2, Slug, or Twist were not altered (data not shown). E-cadherin, an epithelial marker, (our data) and PC9 metastatic cells (public data, GSE14107), which were independently derived using the intracardiac injection mouse metastasis model, revealed 48 differentially expressed genes between R0 and R3 that were common in both systems, with criteria of false discovery rate o1.0 and log 2 fold change 41.5 or o − 1.5. Differentially expressed genes were further narrowed down to 11 based on the unidirectional log 2 fold change across R1, R2, and R3, and including only genes reported to have cancer-associated function. 
cells showed similar pattern of EMT marker change to H358-shLAMC2 (shRNA no. 2) (data not shown), suggesting that the changes observed in EMT markers were not off-target effects of LAMC2 knockdown. These data suggest that LAMC2 may regulate NSCLC migration and invasion through the modulation of EMT.
Secreted LAMC2 enhances cell migration and invasion. LAM-332 was reported to be a scatter or motility factor secreted by tumor cells or normal epithelial cells, inducing motility of gastric cancer, 30 melanoma, 31 and breast cancer cells. 32 To determine whether LAMC2 was secreted by the lung ADC cells, cells were cultivated in RPMI-1640 without additives, serum, or other growth factors for 24 h. The conditioned medium was then collected, followed by ultracentrifugal filter concentration (Supplementary Figure S3A) . Immunoblot analysis using the concentrated conditioned medium identified secreted unprocessed (140 kDa) and processed (100 kDa) LAMC2 (Figure 3a) , whereas the 100 kDa LAMC2 was detected in the cell lysates at much lower level than in conditioned medium (data not shown). Our data are consistent with a previous study showing LAMC2 subunit is subjected to cleavage into a mature form upon extracellular secretion. 33 To investigate whether secreted LAMC2 was a motility factor, conditioned medium was added to Boyden chamber inserts containing LAMC2-knockdown cells for the migration and invasion assays. Conditioned media derived from PC9-shLAMC2 or H358-shLAMC2 cells contained less secreted LAMC2 (Figure 3a ) and induced less migration and invasion (all P-values o0.05; Figure 3b and Supplementary Figure S3B ) than those from PC9-shMock or H358-shMock cells. In addition, migration of LAMC2-knockdown PC9 cells was enhanced by the concentrated conditioned medium in a dose-dependent manner (all P-values o0.05; Supplementary Figure S3C) . Moreover, LAMC2-blocking antibody attenuated A549R0 cell migration and invasion induced by A549R0-LAMC2 cell conditioned medium (all P-valueso0.05; Figure 3c ), suggesting that secreted LAMC2 enhances cell migration and invasion.
LAMC2 knockdown reduces metastasis in mice. To test the in vivo effects of LAMC2 on lung ADC metastasis, we evaluated the metastatic capacity of luciferase-transfected ADC cells in our intracardiac injection metastasis model. In vitro baseline bioluminescent intensities of luciferase-transfected A549R4-shLAMC2 and A549R4-shMock cells were similar or slightly stronger in A549R4-shLAMC2 cells (Supplementary Figure S4A) . Luciferase-positive A549R4-shLAMC2 and A549R4-shMock cells were intracardially injected into nude mice. Serial noninvasive bioluminescent imaging was performed weekly for 4 weeks and then biweekly for the next 2 weeks (Figure 4a ). Selected bioluminescent hot spots acquired by in vivo bioluminescent images were confirmed to be metastatic tumors by histologic examination (Supplementary Figure S4B) . From the first week on, knockdown of LAMC2 consistently reduced metastatic activity of A549R4 cells. At 6 weeks, the average number of metastases per mouse was 1.9-fold lower in A549R4-shLAMC2 cells than in A549R4-shMock cells (4.1 ± 2.1 for LAMC2 knockdown versus 7.7 ± 3.6 for control; P = 0.017; Figure 4b ), indicating that LAMC2 knockdown attenuated metastasis.
LAMC2 promotes migration and invasion via integrin β1-and/or ZEB1-dependent EMT. Previous work showed that LAMC2 binds to integrin α2/β1, 34 and integrin is required for invasion in some tumors. 35 To test whether integrin participates in LAMC2-induced EMT, we first assessed the potential interaction between LAMC2 and integrin in NSCLC cells. LAMC2 pulldown experiments showed that both endogenous and exogenous LAMC2 interacted with integrin β1 in H2122, PC9, and A549R4 cells (Figure 5a ). This was confirmed by the reciprocal integrin β1 pulldown in the same cell lines (Figure 5b ). LAMC2-positive cells secreted LAMC2, suggesting that the secreted LAMC2 may act in an autocrine loop where it binds to integrin β1 receptor on the cell surface, which in turn induces EMT. To validate this hypothesis, we knocked down integrin β1 in LAMC2-negative A549R0 cells treated either with A549R0 conditioned medium, which did not contain LAMC2, or with A549R4 conditioned medium, which was rich in secreted LAMC2. Depletion of integrin β1 led to reduction of N-cadherin expression concomitant with the induction of E-cadherin (Figure 5c ), suggesting that integrin β1 knockdown blocks LAMC2-induced EMT. The same finding was confirmed in LAMC2-positive A549R4 cells where depletion of integrin β1 reversed the EMT signaling (Figure 5d ). Moreover, integrin β1 knockdown reduced migration and invasion of A549R0 and PC9 cells treated with A549R0 and A549R4 conditioned media (Figures 5e and f) , suggesting that integrin β1 may be a downstream effector of LAMC2-mediated EMT signaling.
The fact that blocking EMT by integrin β1 knockdown attenuates LAMC2-mediated migration and invasion suggests that LAMC2 may promote NSCLC migration and invasion through the modulation of EMT. To validate this hypothesis, we investigated whether the impact of LAMC2 on cell migration and invasion is dependent on EMT master regulators ZEB1 and Snail. ZEB1-shRNA knockdown in A549R0-LAMC2 cells Figure S5B) restored cellular migration and invasion (all P-valueso0.05). To investigate the clinical relevance of LAMC2 expression in EMT induction, vimentin immunohistochemistry (IHC) was performed using tissue microarray (TMA) samples of stage I human lung ADCs (Yonsei Cancer Center (YCC) series). High LAMC2 expression was positively correlated with vimentin expression (P = 0.010; 26.0% in high LAMC2 group versus 9.9% in low LAMC2 group; data not shown). In addition, vimentin expression was also correlated with poor recurrence-free survival (P = 0.049; Supplementary Figure S5C) . Taken together, these data suggest that EMT may be one of the mechanisms by which LAMC2 enhances migration and invasion of lung ADC. High expression of LAMC2 predicts poor prognosis in human lung ADC. To investigate the impact of LAMC2 expression on prognosis, three independent public mRNA microarray data sets of radically resected NSCLC patients (Supplementary Table S2 ) were analyzed. High LAMC2 expression was correlated with higher risk of recurrence and death in ADC patients, but not in the SCC patients (Figures 6a-c) by univariate analysis. Multivariate analysis, adjusted by stage, showed that LAMC2 expression remained a significant prognostic factor for patients with pStage I ADC (Supplementary Table S3 ). We also evaluated LAMC2 expression by IHC on a TMA of 250 pStage I NSCLC samples from patients who underwent radical surgical resection (YCC series; Supplementary Table  S2 ). The immunoreactivity of LAMC2 was mainly detected in the cytoplasm of tumor cells, and LAMC2 staining was positive at the epithelial-stromal interface, but not in the core of tumor nests (Figure 6d ), in agreement with previous observations. 38 When the cutoff for LAMC2 positivity was set at 30% (Figure 6e ), 33% of ADC and 25% of SCC cases were categorized as high LAMC2 groups. High LAMC2 was associated with a higher risk of recurrence (P = 0.027) and death (P = 0.012) in ADC but not in SCC (Figure 6f ), although others, by stratifying LAMC2 expression based on the stromal types or LAMC2 distribution in tumors, showed that high LAMC2 expression in lung SCC with fibrous stroma composition or in invasive front of SCC was correlated with tumor aggressiveness. 39, 40 In line with the latter, overexpression of LAMC2 in H1703, a lung SCC cell line, augmented migration and invasion as compared with mock controls (Supplemental Figure 6a) . Whether LAMC2 may have a similar role in lung SCC as in lung ADC remains to be investigated. Intriguingly, using the same criteria described by Takahashi et al., 40 we stratified LAMC2 expression according to the stroma types in our TMA samples, and found that lung ADCs with fibrous stroma, although not associated with elevated LAMC2 expression (P = 0.19), were significantly correlated with worse recurrence-free survival ( Supplementary Figure 6b ; n = 66, P = 0.047). As only limited number of ADCs (n = 66) was evaluable for stroma-type stratification in our TMA samples, more samples are required to draw a definite conclusion. Prognostic significance of LAMC2 in ADC was maintained in multivariate analysis adjusted by stage (IA versus IB) (Supplementary Table S3 ). In summary, both microarray and IHC data indicated that LAMC2 expression is associated with poor prognosis in early-stage lung ADC, which lends strong support to our functional studies that LAMC2 may promote lung ADC metastasis.
Discussion
As tumor cells were intracardially injected into the blood stream in our mouse metastasis model, LAMC2 may enhance metastasis by facilitating extravasation and spreading to Figure 6 High expression of LAMC2 predicts poor prognosis in human lung ADC. (a-c) Kaplan-Meier survival curves according to relative LAMC2 mRNA expression from public mRNA microarray data sets: (a) JNCC (GSE31210), (b) SMC (GSE8894), and (c) DUMC (GSE3141). All patients included in these analyses were curatively resected for NSCLC and never received preoperative therapies. An optimal cutoff point for normalized intensity of LAMC2 mRNA was determined using minimum P-value approach in predicting recurrence-free or overall survival. Survival comparisons and P-values were determined by log-rank test. . (e) Positivity for LAMC2 was assessed from 0 to 100% of stained cells by cytoplasmic or extracellular staining with any intensity. The cutoff of 30% was used for LAMC2 positivity as in previous reports using the same antibody. (f) Kaplan-Meier survival curves according to LAMC2 staining intensity. Survival comparisons and P-values were calculated by log-rank test distant target organs. Cells extend protrusions with lamellipodia or filopodia to initiate extracellular matrix (ECM) recognition and binding to ECM, which are the prerequisites for the onset of cell motility. 41 The extended projected area of A549R0-LAMC2 cells in our biophysical assay may be the result of LAMC2-induced cell protrusion and contractile force, which are required for cell motility. Moreover LAMC2 IHC of lung ADC TMA showed that LAMC2 was predominant in tumor cells at the boundary between tumor and stroma, further supporting a role of LAMC2 in tumor cell spreading.
The clinical relevance of these findings was confirmed by a higher risk of recurrence or death in early-stage ADC patients with high tumor expression of LAMC2. Although adjuvant chemotherapy has been shown to increase survival by about 4% in stages II and III, its use is controversial in stage IB and associated with detrimental effect in stage IA. 42 Strong prognostic factors in early stages of lung cancer are desperately needed, which could discriminate patients with a higher risk of tumor recurrence who might benefit from adjuvant chemotherapy. A plethora of putative prognostic markers have been identified, but most have not been independently validated. We and others 5, 6 demonstrated that LAMC2 protein expression correlated well with clinical outcome of stage I ADC patients, which was further supported by our functional studies in vitro and in vivo metastasis models. Moreover, it has been reported that serum LAMC2 exhibited diagnostic complementarity with CA19.9 in pancreatic ADC allowing earlier detection of primary or recurrent pancreatic cancer. 8 Considering that secreted LAMC2 in the conditioned medium promotes lung cancer cell migration and invasion in our study, it is worth testing if serum or plasma LAMC2 may be used as a predictive biomarker of lung cancer metastasis, particularly in predicting the prognosis of early-stage lung ADC.
Although adjuvant chemotherapy has shown to increase survival in several solid tumors after radical resection (e.g. colon, breast, and lung), its nonspecificity and relatively high toxicity deserve careful consideration. In our study, we demonstrated that an anti-LAMC2 antibody inhibits migration and invasion of lung ADC cells in vitro. Antibody therapy targeting LAMC2 might help delay the metastatic progression by blocking migration and invasion steps of the metastatic cascades. This strategy could complement more specific antitumor therapies. Further studies of this strategy are warranted.
LAMC2 may increase metastatic potential through integrin β1-, ZEB1-, and/or Snail-mediated EMT. We suggest that LAMC2 acts upstream of integrin β1, ZEB1 and Snail, as manipulation of integrin β1, ZEB1, and Snail expression alters LAMC2-induced migration, invasion, and EMT. Evidence suggests that FAK and SRC, through integrating intracellular signals, activate EMT regulators, ZEB1 and Snail. 43 It is possible that the elevated LAMC2 in cancer cells may, through interaction with integrin β1, hijack part of the focal adhesion complex including FAK/SRC kinase 44 to induce EMT via ZEB1 and/or Snail.
In conclusion, our data show that LAMC2 enhances metastatic potential in lung ADC through engagement of EMT. LAMC2 is a strong prognostic marker in early stage ADC of the lung and can potentially be targeted to prevent metastasis.
Materials and Methods
Cell lines. Lung ADC cell lines (A549, NCI-H838, PC9, NCI-H2122, NCI-H358, and NCI-H322) were purchased from American Type Culture Collection (Manassas, VA, USA). All cancer cell lines were maintained in RPMI-1640, supplemented with 10% fetal bovine serum (FBS). Metastatic series of A549, A549R1, A549R2, A549R3, and A549R4, were established by repeated intracardiac injection of A549 in nude mice, as described below. Subconfluent A549 cells in culture were harvested, washed with PBS, resuspended in RPMI medium without phenol red, and injected into mice as described below.
Animal studies with intracardiac injection procedure. Animal experiments were performed in compliance with RARC guidelines of NIH. Fiveto six-week-old female athymic NCr-nu/nu mice (NCI, Frederick, MD, USA) were anesthetized, laid on their back, and the cell suspension was injected into the left ventricle of the heart with a 27.5-gauge needle, through a transdiaphragmatic access. 45 In vivo selection of metastatic derivatives. Gene expression profiling. To discover differentially expressed genes, we compared mRNA expression profiles between round 0 and round 3 cells using both A549 (our metastasis model system) and PC9 ADC cell lines, which is a publicly available data (GSE14107). 21 We used the criteria of false discovery rate o0.1 and log 2 fold change 41.5 or o − 1.5. To evaluate the relationship between LAMC2 mRNA expression level and prognosis in NSCLC, we used three publicly available mRNA microarray data: the first cohort of 204 ADCs from Japanese National Cancer Center (JNCC set; HG-U133A Plus 2.0; GSE31210), 46 the second cohort of a mix of 63 ADCs and 75 SCCs from the Samsung Medical Center (SMC set; HG-U133A Plus 2.0; GSE8894), 47 and the third cohort of 59 ADCs and 52 SCCs from Duke University Medical Center (DUMC set; HG-U133A Plus 2.0; GSE3141). 48 Detailed methods were described in the Supplementary section. IHC in human NSCLC specimens. The expression of LAMC2 and vimentin was determined by IHC from formalin-fixed, paraffin-embedded surgical specimens of 250 patients with NSCLC. All tumor specimens were obtained from a pathological stage I cohort, which underwent complete surgical resection between 1998 and 2007, without neoadjuvant treatment at YCC (Seoul, South Korea). Tumor staging was performed according to TNM staging revised in 2002 by American Joint Cancer Committee. 49 Positivity for LAMC2 was assessed from 0 to 100% of stained cells by cytoplasmic staining with any intensity. The cutoff of 30% was used for LAMC2 positivity as in previous reports with the same antibody. 11, 14, 50 Vimentin was considered to be positive if ≥ 1% of cancer cells were stained in the cytoplasm as reported previously. 51, 52 Detailed methods are described in the Supplementary section.
Fourier transform traction microscopy. Migrating cells exert traction forces upon their surrounding. We measured traction forces of ADC cell lines expressing different levels of LAMC2 using Fourier transform traction microscopy as described previously. 53, 54 Here, the computed traction field was used to obtain net contractile moment, which is a scalar measure of the cell's contractile strength. 54 Net contractile moment is expressed in units of pico-Newton meters (pNm). Detailed methods are described in the Supplementary section.
Conditioned medium and antibody blocking assay. When cells became confluent, RPMI-1640 medium containing 10% FBS was replaced with fresh serum-free medium. After 24 h the conditioned medium was collected and concentrated using Amicon Ultra-Centrifugal filter (Millipore, Billerica, MA, USA) with molecular weight cutoff of 10 kDa at 3800 g at 4°C until 500 μl left on the top of filter (~20 min). For LAMC2-blocking assay, A549R0 cells (8 × 10 5 and 4 × 10 5 cells for migration and invasion, respectively) were suspended in conditioned medium supplemented with 40 μg/ml mouse monoclonal LAMC2 antibody D4B5 (Millipore) as a blocking antibody or mouse IgG antibody as control and were plated in the upper chamber of the transwell plate. Detailed methods were described in the Supplementary section.
In vivo metastasis assay using intracardiac injection and bioluminescent imaging. The same number (1 × 10 5 cells) of A549R4-LUC-shLAMC2 cells (9 mice) and A549R4-LUC-shMock cells (10 mice) in 100 μl volume were injected into the left ventricle of the mouse. Serial bioluminescent imaging was performed weekly for four weeks and then biweekly for the next two weeks. Metastasis was defined as the presence of bioluminescent signals at the same anatomic locations on 3 consecutive images weekly or biweekly. Detailed methods are described in the Supplementary section.
